Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 gp41 membrane-proximal external region (MPER) is a highly conserved, tryptophan-rich segment of the HIV-1 envelope glycoprotein (gp41) located just outside the viral membrane (Montero et al., 2008, Microbiology and Molecular Biology Reviews). The LELDKWASL sequence is a specific linear epitope within the MPER that is recognized by the broadly neutralizing antibody (bNAb) 2F5 (Muster et al., 1993, Journal of Virology). Biologically, this region is essential for the fusion of the viral envelope with the host cell membrane, a process triggered after gp120 binds to CD4 and coreceptors (Zwick et al., 2001, Journal of Virology). In the context of disease, the MPER is a critical target for HIV-1 prevention and treatment because its conservation suggests it is functionally indispensable for the virus (Haynes et al., 2005, Science). Therapeutic strategies involving this target include the administration of monoclonal antibodies like 2F5 or the design of vaccines intended to elicit similar MPER-specific antibodies. However, the epitope's proximity to the lipid bilayer and its tendency to elicit autoreactive antibodies that bind to host lipids like cardiolipin pose significant hurdles for clinical application (Haynes et al., 2005, Science; Alam et al., 2009, PNAS).
Inhibition of viral-cell membrane fusion by sterically blocking the conformational transition of gp41 into its pre-hairpin intermediate state, thereby preventing the formation of the six-helix bundle required for fusion (Zwick et al., 2001, Journal of Virology).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 envelope glycoprotein 41 membrane-proximal external region (MPER) - LELDKWASL epitope (HIV-1 gp41 MPER (LELDKWASL)).